Acute Myeloid Leukemia, Myelodysplastic Syndrome
Conditions
Keywords
Allogreffe, LAM , MDS, Azacitidine (VidazaÒ), Injection de lymphocytes de donneur (DLI)
Brief summary
Patients included in the study with high risk acute myeloid leukemia or myelodysplastic syndrome as defined will receive an allogeneic transplantation conditioned by either myeloablative or reduced regimen. Following allogeneic transplantation, patients will receive a maintenance regimen combining chemotherapy with azacitidine (aza) and immunotherapy with donor lymphocyte infusion.
Interventions
DRUGAzacitidine
Azacitidine (AZA) is to be administered every 28 days beginning day +56 to 100 posttransplant for one year provided the patients has a platelet count of \>15 x 109/L without transfusion for at least 2 successive days, and an absolute neutrophil count of \>1 x 109/L without growth factor for at least 2 successive days, and no acute GVHD greater than grade I and no clinical evidence of life-threatening infection. AZA is given 32 mg /m²/day subcutaneously for 5 days every 28 days (
OTHERDLI
Donor lymphocyte infusion (DLI) is to be given from day +126 (week 18) in patients without immunosuppressive therapy for at least one month and following 3 cycles of AZA, and without clinical signs of GVHD, and without uncontrolled infection and without a recent history of \>grade 2 acute GVHD. DLI are schedules every 8 weeks. There are 3 DLI scheduled. If first cycle of AZA is postponed beyond day 56 (maximum to Day 100), all subsequent cycles and DLI will be post poned too.
Sponsors
Nantes University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients with high risk acute myeloid leukemia undergoing allogeneic transplantation with either a familial or an unrelated donor. High risk AML is defined as : * AML in CR1 with unfavorable cytogenetics defined by complex caryotype, autosomal monosomy combined or not with other cytogenetics abnormalities inv(3)/t(3,3), t(6;9), t(6;11), t(11;19), del(5q), del(7q). * AML in CR2 or greater remission prior allogeneic transplantation * AML in PR or relapse prior allogeneic transplantation * Or Patients with high risk myelodysplastic syndrome undergoing allogeneic transplantation with either a familial or an unrelated donor. High risk MDS is defined as : * MDS with intermediate-2 group and higher risk group according to IPSS criteria * Age 18 - 70 years. * Availability of an HLA identical family donor or unrelated donor with matching in 10/10 alleles (HLA-A, B, C, DRB1, DQB1) or maximum of 1 allele or antigen mismatch OR family donor with maximum 1 allele mismatch. * Conditioning regimen to allogeneic transplantation may be either myeloablative or reduced. * Be able to understand and sign informed consent. * Affiliation number to National Health Care System * Men and women of childbearing potential must use effective contraception during and up to 3 months after treatment.
Exclusion criteria
* The presence of any one
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the cumulative incidence of relapse rate | 2 years | An A'Hern procedure will be used (cf. 11.1): If the number of patients not relapsed at two year will be 18 or more out of 24 patients, the null hypothesis will be rejected and the relapse rate will be considered acceptable. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measure the overall survival rate at 2 years | 2 years | Kaplan-Meier method |
| Cumulative incidence death from leukemia, and non relapse mortality (NRM) | 2 years | cumulative incidence function for disease free survival at 2 years from transplantation, GVHD, death from leukaemia and non-relapse mortality will be estimated (patients are at risk not only for relapse but can also be removed from possible relapse because of competing events such as death in remission (due to infection or GVHD)). |
| Evaluation of disease-free survival (DFS) at 2 years from transplantation | 2 years | Kaplan-Meier method |
| Feasibility and safety of performing prophylactic donor lymphocytes infusion | 2 years | The relatedness of observed toxicity to DLI will be evaluated and documented: * Maximum toxicity with respect to mucositis, liver, kidney, lung, heart, neurological system according to CTC criteria (cf. appendices). * Infections (bacteremia, fungemia, invasive fungal infection, CMV reactivation and disease, other viral reactivation or infection). * Grade of acute and chronic GVHD (cf. appendices); GVHD is classified according to clinical symptoms, irrespective to the time interval to DLI. * Bone marrow aspiration, as well as chimerism in PB. |
| Incidence and severity of acute and chronic graft-versus-host disease | 2 years | Symptoms related to GVHD should be reported within the GVHD section of the case reporting files. AE and SAE are documented in the patient's chart * on a daily basis, as long as the patient is on ward, and * on a weekly to two-monthly basis during outpatient follow up, depending on the frequency of outpatient visits on the respective patient. |
| Feasibility and safety of administrating maintenance azacitidine following allogenic transplantaton | 2 years | To evaluate toxicity induced by the azacitidine and DLI, different parameters will be studied:Cell Blood Count with differential, liver function tests, serum creatinine, BUN and total protein will be performed weekly from the time of initiation of azacitidine administration until completion of the last DLI. Performance Status,Acute GVHD,Bone marrow aspiration with evaluation of morphological response as well as chimerism from peripheral blood will be performed prior starting azacitidine, following 3 cycles of azacitidine and after the seventh cycle and twelfth cycle of azacitidine. |
Countries
France
Outcome results
None listed